Skip to main content
Fig. 3 | Molecular Cancer

Fig. 3

From: CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K/AKT pathway

Fig. 3

CircWAC decrease chemosensitivity to PTX in TNBC. a, b The efficiency of circWAC overexpression and silencing in MDA-MB-231 and MDA-MB-468 cells was verified by qRT-PCR. c-f Cells were treated with PTX (concentrations of 0, 5, 10, 15, 20, 25 and 30 μmol/L) for 24 h, and cell viability was evaluated by a CCK-8 assay. g-j Cells were treated with paclitaxel (0 and 20 μM) for 24 h, and cell viability was evaluated by a colony formation assay. k, l Cells were treated with paclitaxel (0 and 20 μM) for 24 h, and the apoptosis rate was analyzed via flow cytometry. The data are presented as the means±S.D. of at least three independent experiments. m The expression of circWAC was significantly increased in the chemotherapy resistance patients. *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page